1 in 3 achieved undetectable molecular disease at 24 months.
ONCOLOGY
Fully funded by 
Content independently selected
-
Chronic-phase CML: frontline nilotinib delivers high-level response, adherence -
CML-CP: imatinib delivers excellent response with low toxicity in very old patients 7 in 10 patients achieved complete cytogenetic response.
-
AML: add-on nivolumab safe, effective with standard induction therapy Median EFS not reached at time of analysis.
-
Frontline AML: real-world data confirm decitabine safety, efficacy Adverse cytogenetics, higher WBC predicted inferior survival.
-
MDS: certain demographic factors prognostic of favorable survival Factors including married status prognostic of favorable survival.
-
CLL: ibrutinib delivers improved survival vs conventional 2L therapies Venetoclax may be a better option in patients with 13q14.3 deletion.
-
Frontline ibrutinib-rituximab tops chemoimmunotherapy for CLL 65% reduction in risk for progression or death.
-
Remission with ibrutinib + venetoclax in relapsed chronic lymphocytic leukaemia Findings from the CLARITY trial published in the Journal of Clinical Oncology
-
R/R B-ALL: can transplantation prolong benefits of CAR-T cell therapy? Significant improvement in EFS, RFS in select patients.
-
ND CLL: fixed-duration strategy with obinutuzumab+ibrutinib can spare many from chemotherapy Impressive outcomes following 12 months of fixed-duration treatment.
-
ALL survivors: visual short-term memory deficits mimic older age Findings may help inform cognitive remediation programs.
-
Elderly AML: which factors predict in-hospital mortality after ICU admission? Findings may help inform critical decision-making.
-
R/R CLL: venetoclax+ibrutinib delivers high MRD negativity in phase 2 More than 50% of patients were MRD-negative in peripheral blood.
-
Molecular characterization of pediatric mixed phenotype acute leukemia Rare disease shows no distinct molecular characteristics.